NOW FDA APPROVED:

ZURZUVAE^™ (zuranolone),
for the treatment of women
with postpartum depression*

*Pending scheduling by the U.S. Drug Enforcement Administration

LEARN MORE

Seeing the brain differently
makes a world of difference

Learn More About Our Approach

News The latest from Sage

See All News

PATIENTS & CARE PARTNERS Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by brain health disorders.

See our resources for patients

Asian woman on a solid blue background wearing a gray t-shirt and a ponytail looking off into the distance

HEALTHCARE PROVIDERS It’s an exciting time in neuroscience

At Sage, our goal is to originate meaningfully differentiated drug candidates. We aim to discover new pathways to brain health by making medicines that matter so patients can get better, sooner.

LEARN MORE ABOUT OUR APPROACH

CLINICAL TRIALS A distinct approach to neuroscience drug development

Sage is committed to developing new medicines to treat life-altering brain health disorders.

LEARN MORE ABOUT OUR ONGOING CLINICAL TRIALS

PIPELINE Advancing a leading brain health portfolio

We seek to make a positive impact on the unmet treatment needs of patients by advancing product candidates from a robust development pipeline of potential brain health disorder treatments.

Compound

Potential Indications

Phase 1

Phase 2

Phase 3

FDA Approved

Marketed

Postpartum Depression Franchise

ZULRESSO^®
(brexanolone) CIV injection

Postpartum Depression

100

ZURZUVAE^™*
(zuranolone)

Postpartum Depression

NEUROPSYCHIATRY FRANCHISE

Zuranolone*
(SAGE-217)

Major Depressive Disorder**

SAGE-718

Huntington's Disease Cognitive Dysfunction

Parkinson's Disease Cognitive Dysfunction

Alzheimer's Disease Mild Cognitive Impairment and Mild Dementia

SAGE-324*

Essential Tremor

PROGRAMS IN EVALUATION

⚫ SAGE-689 Acute GABA Hypofunction
⚫ SAGE-421 NMDA Hypofunction
⚫ SAGE-319 GABA Hypofunction

*Collaboration Partners: Biogen Inc., and Shionogi for zuranolone and Biogen Inc. for SAGE-324
**The FDA issued a CRL on August 4, 2023, related to the NDA for the treatment of adults with MDD stating that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies will be needed. No Phase 3 trials are currently ongoing.

Please refer to the U.S. Prescribing Information for ZULRESSO and the U.S. Prescribing Information for ZURZUVAE
Safety and efficacy for investigational uses or compounds have not been established. There is no guarantee that the outcome of these studies will be positive or result in approval by a Health Authority.

LEARN MORE ABOUT OUR PROGRAMS AND RESEARCH

CAREERS Rethinking brain health disorders to make life better for patients and their families

Sage is a place where unconventional thinking to solve problems with new ideas is welcome - and where unconventional thinkers can imagine what's possible and do big.

EXPERIENCE OUR CULTURE

INSIGHTS & POINT OF VIEW Sage Thoughts

News The latest from Sage

press releases

events

sage thoughts